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ABSTRACT
Purpose: In this study, we investigated the differences in hyperthermia treatment (HT) quality between
treatments applied with different hyperthermia systems for sub-superficial tumours in the head and
neck (H&N) region.
Materials and methods: In 24 patients, with a clinical target volume (CTV) extending up to 6 cm from
the surface, we retrospectively analysed the predicted HT quality achievable by two planar applicator
arrays or one phased-array hyperthermia system. Hereto, we calculated and compared the specific
absorption rate (SAR) and temperature distribution coverage of the CTV and gross tumour volume
(GTV) for the Lucite cone applicator (LCA: planar), current sheet applicator (CSA: planar) and the
HYPERcollar (phased-array).
Results: The HYPERcollar provides better SAR coverage than planar applicators if the target region is
fully enclosed by its applicator frame. For targets extending outside the HYPERcollar frame, sufficient
SAR coverage (25% target coverage, i.e. TC25 75%) can still be achieved using the LCA when the tar-
get is fully under the LCA aperture and not deeper than 50mm from the patient surface.
Conclusion: Simulations predict that the HYPERcollar (hence also its successor the HYPERcollar3D) is to
be preferred over planar applicators such as LCA and current sheet applicator in sub-superficial
tumours in the H&N region when used within specifications.
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Introduction
Adding hyperthermia (HT) to radio- and/or chemotherapy
has been demonstrated to be beneficial for treatment out-
come for a number of cancers at various locations in the
body [1–4]. It is commonly accepted that hyperthermia treat-
ment quality is positively correlated with improved tumour
control [2,5]. Hence, during the last decades ample research
has been devoted in developing hyperthermia systems for
superficial or deep heating that provide the ability of a flex-
ible and adaptive optimisation of the delivered thermal dose
for a specific tumour site [6–8]. At our institute, superficial
hyperthermia is administered at 434MHz using incoherent
planar applicators, i.e. the Lucite cone applicator (LCA) or the
current sheet applicator (CSA), to treat diseases up to 40mm
from the surface [9]. For the deeper and more centrally
located tumours in head and neck (H&N) region, we devel-
oped the HYPERcollar applicator consisting of 12 patch
antennas arranged in two rings operating coherently at
434MHz [10]. The HYPERcollar is based on phased-array heat-
ing technology, allowing 3D steering of the heat focus to the
target region.
Prior to each HYPERcollar treatment, a hyperthermia treat-
ment planning (HTP) is required to obtain information about
the optimal amplitude and phase settings for each channel
in the phased array, and the patient position in the applica-
tor [11,12]. For hyperthermia target definition, we use identi-
cal delineation to the clinical target volume (CTV) used for
radiotherapy. Our in-house developed visualisation tool for
electromagnetic dosimetry and optimisation, i.e. VEDO, is
used to optimise amplitude and phase settings during treat-
ment according to measured temperatures and patient feed-
back [13]. Pre-treatment planning in superficial hyperthermia
is not regularly required and is applied only in special situa-
tions: if the CTV is 1) deeper than 40mm, 2) close to critical
organs or 3) includes metal implants [14,15]. We consider
HTP an ideal tool for comparison of different treatment
modalities.
The purpose of this study was to extend current HT strat-
egies by including also applicator selection in the overall
optimisation process for sub-superficial tumours in the head
and neck region. For 24 representative patients, we retro-
spectively compared quality of hyperthermia treatments
using HTP for the HYPERcollar, LCA and CSA applicators. HTP
for the HYPERcollar was done following our standard clinic
procedure [16] and superficial HTP setups for LCA and CSA
were created manually by an experienced physicist. Heating
quality was assessed using the predicted specific absorption
rate (SAR) and temperature coverages of the CTV.
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Methods
Patient selection
We selected all patients referred for HT treatment in the H&N
region with the CTV extending up to 6 cm from the patient
surface, leading to 24 patients in total. 19/24 patients were
treated with the HYPERcollar applicator, 3/24 with a setup of
1–6 LCAs (depth CTV 4 cm) and 2/24 were not treated due
to insufficient SAR coverage. The latter two patients were
included in this study to provide situations with a larger vari-
ation in the SAR and temperature coverage for the
HYPERcollar applicator. The group of 24 patient models com-
prised of 13 larynx, six oral cavity, four oropharynx and one
nasopharynx tumour, i.e. 18 males and six females with
mean age of 64.3 ± 10.1 (1 standard deviation) years.
Hyperthermia treatment planning
The patient specific HTP procedure involves finding the opti-
mal hyperthermia system setting (e.g. applicator type and
position, amplitude, phase, water bolus temperature) to
maximise the heat delivery in the CTV. At our institute, HTP
is mandatory prior to HYPERcollar treatments to optimise
amplitude and phase settings for each channel in the phase
array, and the patient position in the applicator [11,12,16].
HTP also ensures that the specific absorption rate (SAR) in
critical tissues such as spinal cord does not exceed safety lim-
its of 60W/kg [13]. Our in house tool VEDO allows techni-
cians to adjust amplitude and phase settings during
treatment according to measured temperatures and patient
feedback [13]. Superficial HTP setups were created manually
by an experienced physicist (TD) in order to overlap the CTV
with at least ten millimetres by the LCA or CSA aperture.
Heating quality was assessed using the predicted specific
absorption rate (SAR) and temperature coverage of the CTV
and gross target volume (GTV), i.e. tumour.
Patient model
Patient specific 3D models were automatically segmented
from on average 166± 44 computer tomography (CT) slices
using an atlas-based method [17,18]. Adjustment of air at
nose and ear cavities, metal implants and assignment of
tumour from radiotherapy planning delineation was done
manually in iSeg (v. 3.8, ZMT, Z€urich, Switzerland). Patient
models typically consisted of 15 tissues and it takes around
40min of processing power plus 20min of operator time to
create 3D patient model at a standard desktop computer.
Sclera, optical nerve and vitreous humour were segmented
separately for left and right eye. Figure 1(a) shows a simpli-
fied 3D patient model with the CTV and GTV highlighted.
HYPERcollar H&N hyperthermia
One point at the top of the nose and two at the edges of
the headrest were assigned in iSeg together with the patient
model and imported into electromagnetic simulator SEMCAD
X (v. 14.8.6, Speag, Z€urich, Switzerland). These points were
used for automatic positioning (translation and rotation) of
the HYPERcollar model such that the patient model was at
the identical position as during the test treatment. For each
antenna, a harmonic electromagnetic simulation was calcu-
lated using SEMCAD X, and 3D electric (E)-field distributions
per antenna were exported. These fields were combined in
VEDO, and amplitude and phase per field were optimised
[13]. Figure 1(b) shows an example of HTP setup using the
HYPERcollar applicator. Within this study we were able to
create HTP setups for all 24 patient models using the
HYPERcollar applicator.
LCA or CSA H&N hyperthermia
Since superficial arrays are excited in incoherent mode, opti-
misation of 3D SAR pattern consists of changing the
respective power and/or position of each applicator in the
array. This makes superficial treatment planning laborious
and distinctly different from deep (phased-array) HTP, where
individual antennas are fixed with respect to each other. All
simulation setups for superficial HTP in this study were cre-
ated manually in SEMCAD X to enclose the CTV within 50%
SAR iso-surface. In clinical practice this translates to overlap-
ping the CTV with the LCA and/or CSA aperture by a mar-
gin of at least 10mm, which is visualised in Figure 2(b). For
each patient, we studied all possible applicator configura-
tions, e.g. single and/or multiple applicator setups and
whenever possible two E-field orientations per applicator.
Figure 1(c) shows an example of a HTP setup using a com-
bination of two LCAs, Figure 1(d) shows a setup with an
array of three CSAs. For the CSA, creation of HTP setups for
all 24 patient models was possible, while proper positioning
of the LCA during HTP was not possible for two patients
due to its large aperture.
EM and temperature calculations
The electromagnetic field simulation settings in SEMCAD X
for all three applicators are summarised in Table 1. We used
a uniform FDTD (Finite Difference Time Domain) step of
1.25mm for all HYPERcollar simulations. For the CSA/LCA, the
feeding parts were modelled using a graded step size
(0.05mm, 0.5mm), while using maximum 1mm inside the
applicators and maximum 5mm outside the applicators. The
small FDTD grid step of 0.05mm, necessary to correctly dis-
cretize the inner part of the applicator, resulted also in
increased calculation time for the CSA. The metal parts of all
applicators were modelled as perfect electric conductor (PEC)
material and voxelled as continuous volume. Compute uni-
fied device architecture (CUDA) acceleration at two GTX Titan
graphic cards in SEMCAD X was used for all electromagnetic
(EM) simulations. All dielectric and temperature properties,
shown in Table 2, were assigned using the ITIS material data-
base [19]. The temperature distribution were calculated using
the Pennes bioheat [22] equation
cq
oT
ot
¼ r krTð Þ  SFqbcbqx T  Tbð Þ þ qSARþ qQ
where c (J/kgK) represents the specific heat capacity,
q (kg/m3) the density, k (W/mK) the thermal conductivity,
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Figure 2. CTV and GTV fully (a) within the frame of the HYPERcollar, (b) under the LCA aperture.
Figure 1. (a) Patient 3D model in SEMCAD X with highlighted CTV and GTV (homogeneous transparent patient model was used for better visualisation of CTV and
GTV). Example of treatment planning setups for all studied applicators, (b) HYPERcollar, (c) Lucite cone applicator and (d) current sheet applicator.
Table 1. Summary of electromagnetic simulation settings in SEMCAD X.
Model Global grid step (mm) Refined grid step (mm) Periods () Size (Mcells) Calculation time (min.)
LCA 5 1/0.5 35 15 10
CSA 5 1/0.05 25 65 30
HYPERcollar 1.25 – 15 75 8
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cb (J/kgK) the specific heat capacity of blood, x (ml/minkg)
the blood perfusion rate, Q (W/kg) the metabolic heat gener-
ation, Tb (K) the temperature of the circulated blood and SF
() is a scaling factor used to implement temperature
dependent blood perfusion model [23–25] for muscle, fat
and tumour which is shown in Figure 3. We studied two tem-
perature models
 optimised constant values (xconst.) – blood perfusion and
thermal conductivity as reported by Verhaart et al. [21],
optimised to minimise the difference between measured
and predicted temperature profiles.
 temperature dependent perfusion (xTdep.) – blood perfu-
sion for fat was piecewise linearly scaled by factor of 2,
for muscle by factor of 8.9 and for tumour by factor of
0.5 between temperatures of 37 C and 45 C shown in
Figure 3, for all other tissues the scaling factor SF¼ 1.
For all temperature simulations, we used a uniform 2mm
FDTD discretization, a double precision solver and one hour
of heating (treatment) time. Internal air together with metal
implants and lung were inactive in the temperature simula-
tions and modelled using mixed boundary condition with
heat transfer rate h¼ 82W/m2K and h¼ 50W/m2K, respect-
ively and temperatures of 20 C and 37 C. Boundary condi-
tions with h¼ 8W/m2K and temperatures of 20 C were used
for external air and the headrest [21].
Optimization and evaluation
In clinical practice, we use as inclusion criteria for both H&N
and superficial treatments that at least 75% of the CTV must
be enclosed by the 25% iso-SAR contour [13]. The optimum
SAR distribution for the HYPERcollar is obtained using par-
ticle swarm optimisation algorithm that maximises the tar-
get-hotspot quotient (THQ) representing the ratio of average
SAR in the target and hotspot in VEDO [13]. For the LCA and
CSA models, we scaled RF power input to individual applica-
tors to obtain equal maximum SAR under each applicator
aperture. SAR for all three applicators was adjusted to
achieve maximum of 43 C in normal tissue, i.e. outside GTV.
Results
Patient selection
Figure 4(a) shows cumulative volume size histograms for
the CTV and GTV of all 24 patients in this study. We found
a median CTV and GTV volumes of 84 cm3 and 39 cm3.
Note that seven patients had no GTV since they were
treated with radiotherapy combined with hyperthermia after
surgical removal of the tumour (“post-operative”). Because
of lower number of GTVs, we decided to make further ana-
lysis only based on CTV targets. Figure 4(b) shows mean
CTV depth profile including minimum and maximum inter-
val, maximum CTV depth from the patient surface was
54 ± 10.9mm (mean ± standard deviation). Please note that
Table 2. Dielectric properties at 434MHz [20], thermal properties for 37 C [19],  optimised values from ten patients treated with HYPERcollar applicator [21],
the internal air and lung were modelled in temperature simulations using boundary condition.
Tissue er (–) r (S/m) q (kg/m
3) c (J/kgK) k (W/mK) x (ml/minkg) Q (W/kg)
Air 1 0 1.2 – – – –
Blood – – 1050 3617 – – –
Bone 13.1 0.09 1908 1312 0.32 10 0.15
Brainstem 55.1 1.05 1046 3630 0.51 559 11.4
Cartilage 45.1 0.6 1099 3568 0.49 35 0.54
Cerebellum 55.1 1.05 1045 3653 0.51 763 15.5
Cerebrum 56.8 0.75 1045 3696 0.55 763 15.5
Fat 11.6 0.08 911 2348 0.21/0.5 32.7/255 0.51
Lucite 2.6 0.003 1000 – – – –
Lung 23.6 0.38 394 – – – –
Muscle 56.7 0.8 1090 3421 0.49/0.4 39.1/442.8 0.96
Optical nerve 35 0.46 1075 3613 0.49 160 2.5
Sclera 57.4 1.01 1032 4200 0.58 380 5.9
Spinal cord 69 1.53 1005 4047 0.59 160 2.5
Tumour/GTV 59 0.89 1050 3950 0.51/1.5 72.3/848 0
Thyroid 61.3 0.89 1050 3609 0.52 5624 87
Vitreous humour 69 1.53 1005 4047 0.59 0 0
Water 78 0.04 1000 – – – –
Following the Lang et al. [24] model, the rest value for tumour perfusion is 1.85 times higher than the rest value for muscle perfusion.
37 38 39 40 41 42 43 44 45 46 47
0
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 Temperature (°C)
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Figure 3. Piecewise linear temperature dependent perfusion scaling factors
for muscle, fat and tumour. Please note that the perfusion at the specified
temperature is obtained by multiplying the perfusion value at 37 C with the
temperature dependent scaling function.
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some of the CTV exceed maximum intended depth of 6 cm,
which was caused by fact that at the beginning of the
study patients were selected by manual inspection of the
CT images.
EM and temperature prediction
Figure 5(a) shows the cumulative SAR histograms in the CTV
for the three studied applicators for an example patient.
Figure 5(b,c) shows CTV temperature volume histograms for
constant (5 b) and temperature dependent (5c) perfusion
models. Figure 5(d–f) shows CTV depth profiles of the SAR
normalised to obtain maximum of 1W/kg in the patient
model and the two temperature models. Solid lines represent
the mean values while the whiskers indicate the ± standard
deviation range over the CTV depth, which spanned
18mm–50mm depth. Figure 5(d) demonstrates the deep
heating capabilities of the HYPERcollar applicator: the max-
imum mean SAR is at 36mm depth from the patient surface.
For both superficial applicators this maximum is located at
18mm, which is the minimum depth of the CTV for this
patient. The large and a priori unknown variation in blood
perfusion especially in head and neck region could result in
large uncertainty in the predicted temperature distribution.
In this example, T50 for the HYPERcollar changes from
41.2 C to 41.8 C and for the LCA from 38.8 C to 41.6 C
when going from constant perfusion values to the tempera-
ture-dependent model (see Figure 5(b,c)). For all 24 patients,
we found an average temperature T50 increase of 2.0 C for
LCA, 2.0 C for CSA and 1.6 C for HYPERcollar when applying
temperature-dependent perfusion instead of constant perfu-
sion model. Therefore, we decided to use mainly SAR cover-
age for further analyses.
Figure 6(a,b) shows comparison of TC25 for LCA and CSA
applicators against HYPERcollar for CTV, encircled points indi-
cate comparisons for setups where the CTV was fully posi-
tioned within the frame of the HYPERcollar (see Figure 2(a)).
There are only 22 comparisons for LCA vs. HYPERcollar in
Figure 6(a), since for two patients we were not able to create
HTP setups for the LCA. In 2/24 CSA provided better, in 3/24
comparable and in 19/24 a worse TC25 coverage than the
HYPERcollar (see Figure 6(b)). Because only in 2/22 patients
CSA provided slightly (by 2.9% and 4.6%) better TC25 than
the LCA, we limited all additional comparisons to LCA and
HYPERcollar.
For five patients, with a CTV outside the HYPERcollar
frame, LCA provided better TC25 than the HYPERcollar
(above identity line in Figure 6(a)). These CTVs were located
in the lower part of the neck and extended towards the ster-
num. When the CTV was fully positioned within the
HYPERcollar frame (ten patients), the HYPERcollar was better
7/10 or equal 2/10 to the LCA, and worse only for 1/10
patient. Normalized cubic-filtered SAR (%) distributions
from VEDO are shown for this patient in Figure 7. This
figure compares a) LCA (TC25LCA¼86%), b) HYPERcollar
(TC25HYPERcollar¼62%) and c) modified HYPERcollar
(TC25HYPERcollar¼78%). When re-optimizing phase/amplitude
settings, TC25 coverage could be improved for the
HYPERcollar, but at the cost of the THQ (Figure 7: from 1.73
to 1.48, vs. 1.12 for the LCA).
Figure 8(a) shows the correlation of the TC25 difference
between HYPERcollar and LCA as function of CTV volume for
the 22/24 patients where LCA-based HTP was possible. Based
on the fitted linear line, the LCA provides better TC25 cover-
age than the HYPERcollar when CTV volumes are larger than
137 cm3. Correlations of the T50 difference between
HYPERcollar and LCA for constant and temperature depend-
ent perfusion models are shown in Figure 8(b,c), respectively.
Results from constant perfusion model leads to identical CTV
volume of 137 cm3 found using SAR TC25 analyse. The ther-
mal-dependent model results in a smaller CTV volume of
97 cm3, due to the lower average T50 increase between the
constant and the temperature-dependent model of the
HYPERcollar compared to the LCA. A TC25 difference less
than 1.5% was found in 2/22 patients located fully within the
HYPERcollar frame and also under the LCA aperture, but with
a CTV not exceeding 40mm depth. These results confirm our
approach of using the superficial hyperthermia LCA array in
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Figure 4. (a) CTV and GTV volume cumulative histograms for 24 CTVs and 17 GTVs, (b) mean CTV depth profiles including minimum and maximum depth interval.
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the H&N region when the CTV does not exceed 40mm depth
and the CTV can be covered with LCA aperture.
Figure 9 shows the variation of TC25LCA against maximum
CTV depth for 14 CTVs that were fully under the LCA
aperture (see Figure 2(b)). Based on the fitted linear data, for
CTV with maximum depth of 50mm we obtained
TC25 75%, which is the inclusion criterion for HT in the
H&N region at our institute.
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Figure 5. Example of SAR and temperature cumulative histograms and depth profiles for Lucite cone applicator (LCA), current sheet applicator (CSA) and
HYPERcollar applicator (HC). CTV (a) cumulative SAR histograms; (b) constant perfusion model (xconst.), temperature histograms; (c) temperature dependent perfu-
sion model (xTdep.) temperature histograms; (d) mean SAR ± standard deviation (SD) range; (e) mean temperature ± SD range for (xconst.) and (f) mean
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within HYPERcollar frame are encircled with red colour. Note that for two LCA vs. HYPERcollar comparisons we received almost identical values resulting in partly
overlapping of two points.
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Discussion
The HYPERcollar proved to be the preferred applicator over
superficial hyperthermia applicators for targets positioned
fully within its frame. Only for one single patient with the
CTV fully within HYPERcollar frame, the LCA obtained better
TC25 than HYPERcollar. This can be explained by higher
(better) THQ, used as an objective function for all
HYPERcollar optimisation, in comparison to THQ value
obtained for LCA. For five patients with CTV in larynx
region and the target outside of the HYPERcollar frame, the
LCA achieved better TC25. Our analysis shows that the LCA
can provide a high quality HT treatment in the larynx
region if the CTV is covered by the aperture and the max-
imum CTV depth does not exceed 50mm. Hence, we might
consider changing the general threshold from 40mm to
50mm in our current practice for larynx tumours. Note that
these conclusions are valid only for the LCA, which has a
depth optimised SAR profile, and are not valid for other
superficial applicators like the CSA due to the different SAR
characteristics.
The HYPERcollar3D, i.e. second generation of the applica-
tor, provides equal or better SAR coverage than the
HYPERcollar [26] and thus all conclusions drawn for the
HYPERcollar within this study will be applicable also for
HYPERcollar3D. One of the main redesign aspects of the
HYPERcollar3D compared to HYPERcollar was the reproduci-
bility of the water bolus [26,27]. However, the consequence
for this more reproducible water bolus is the current inability
to treat larynx tumours, as the current water bolus design of
the HYPERcollar3D does not cover the lower neck region.
Due to this inability to properly heat larynx tumours with the
HYPERcollar3D, treatments using the LCA represent a rele-
vant treatment option for this patient group.
For temperature simulations we applied two models in
this study, one with constant temperature conductivity and
the perfusion optimised for the HYPERcollar applicator and
a second more generic model with a temperature-
dependent blood perfusion. These simulations led to differ-
ent observations regarding applicator performance. The
results of the temperature-dependent blood perfusion
model would in some cases even advocate superficial appli-
cators compared to the HYPERcollar applicator while the lat-
ter clearly provided better SAR profiles. For superficial
applicators, we found differences up to 3 C between these
two temperature models. Based on these large differences,
we decided to base conclusions in this study purely on the
SAR coverage. We feel that our state-of-the-art temperature
simulations failed to consistently pinpoint favourable appli-
cators, which confirm our believe for a need of more reli-
able thermal model. These uncertainties in temperature
prediction are one of the main reasons why at our institute
we currently use only SAR coverage for treatment guidance
in clinical practice.
In current clinical hyperthermia practice, selecting the best
applicator system is not often required. However, in our insti-
tute we have the unique opportunity of multiple heating sys-
tems for hyperthermia in the H&N region, i.e. phased arrays
(HYPERcollar and HYPERcollar3D) and planar arrays (six LCA
or CSA elements). Making the selection is still mostly a quali-
tative, expertise-based process with as main criteria the
tumour location and the ability to properly position the heat-
ing system at the patient. For the HYPERcollar treatment,
HTP is always required in order to decide on the optimal
phase and amplitude settings of the 12 antennas. With the
HYPERcollar, nearly the whole patient’s head is enclosed by
the surrounding water bolus and positioning of the applica-
tor must be highly precise in order to accurately translate
the HTP to the clinical setting. For a planar array of LCA or
CSA elements, HTP is performed only in exceptional cases,
and also antenna positioning is less critical, allowing more
flexibility to address patient’s requirements for comfort. Note
though that this lower antenna positioning accuracy also in
turn makes HTP less predictive. Another benefit of superficial
HT is that it requires less personnel [9]. The results reported
in this study represent our attempt to apply more objective
Figure 7. Example of normalised cubic-filtered SAR (%) axial slices in VEDO for (a) Lucite cone applicator, TC25¼ 86%; (b) initial HYPERcollar optimisation,
TC25¼ 62% and (c) modified HYPERcollar optimisation which was done in order to improve TC25¼ 78%, however the target-to-hotspot quotient (THQ) decreased
from 1.73 for case (b) to 1.48 for case (c); for case (a) LCA THQ ¼1.12. Note that the CTV delineation for LCA and HYPERcollar differs slightly due to the different
FDTD grid implementation in SEMCAD X.
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criteria and to improve our process of applicator selection for
tumours in H&N region. To our knowledge, this is the first
clinically based study comparing different heating strategies
for (sub-superficial) hyperthermia using incoherent and
coherent applicators.
The superficial hyperthermia simulation setups were cre-
ated manually by placing applicators to the appropriate
treatment position. The LCA provided better SAR coverage of
the CTV than CSA in 20/24 patients, which was caused by
the depth optimised SAR pattern of the LCA and hence high
effective field size (92cm2) with respect to its aperture size
[28]. For two patients, it was not possible to place the LCA
into the correct position due to the size of the LCA aperture
of 10	 10 cm2. In case of CSA, we were able to build treat-
ment setups for all patients in this study. On the other hand,
the rectangle CSA shape made generation of simulations set-
ups more difficult, while the square aperture of the LCA
allowed to easily study two E-field orientations. Note that
these orientations are often used in sequential treatments to
improve treatment quality robustness. Experience obtained
by building the HTP models revealed that an applicator with
a square aperture around 50–60mm will provide easier appli-
cator placement and better patient contour conformity. To
provide good heating, the EFS should always preferably be
equal to the footprint of the applicator. Nevertheless, still a
possible decrease in penetration depth needs to be consid-
ered during the design procedure for applicators with a
smaller aperture [29,30]. A confounding factor in this study
was the patient position during the CT scan. All 24 patient
models used for this study were generated for a HYPERcollar
treatment. This implied that patient position during the CT
scan was fixed using a H&N mask. This limited the placement
of superficial applicators since patients would preferably be
positioned on a bed facing sideways to expose a larger part
of the neck. This may affect the SAR and temperature cover-
ages, especially for the LCA, however, we do not know to
(a)
(b) (c)
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CT
V 
vo
lu
m
e 
(cm
3 )
−60 −50 −40 −30 −20 −10 0 10 20 30 40 50 60
0
50
100
150
200
250
300
350
400
450
R2=0.48
 HYPERcollar is better LCA is better
 T50HYPERcollar,ω
const.
−T50LCA,ω
const.
 (°C)
 
CT
V 
vo
lu
m
e 
(cm
3 )
−2.5 −2 −1.5 −1 −0.5 0 0.5 1 1.5 2 2.5
0
50
100
150
200
250
300
350
400
450
R2=0.48
 HYPERcollar is better LCA is better
 T50HYPERcollar,ω
Tdep.
−T50LCA,ω
Tdep.
 (°C)
 
CT
V 
vo
lu
m
e 
(cm
3 )
−2.5 −2 −1.5 −1 −0.5 0 0.5 1 1.5 2 2.5
0
50
100
150
200
250
300
350
400
450
R2=0.47
Figure 8. (a) correlations between TC25HYPERcollar–TC25LCA and 22 CTV volumes, correlations between T50HYPERcollar–T50LCA using (b) constant perfusion model and
c) temperature dependent perfusion model.
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what extend as some patients also have a limited ability to
turn the head. In addition, application of the mask allows dir-
ect use of the CTV and GTV that are standardly delineated
for radiotherapy treatment planning for HT purposes, result-
ing in faster and easier to apply HTP process.
Conclusion
This simulation study shows that phased-array applicators
like the HYPERcollar provide better SAR coverage for all
patients than superficial applicators when used within specifi-
cations, i.e. the target region is fully enclosed by the applica-
tor frame. For targets extending outside the HYPERcollar
frame, planar arrays like multiple LCAs can be considered if
the target can be covered with its aperture and is located
less than 50mm from the skin.
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Figure 9. Dependency of TC25LCA and 14 maximum CTV depths for CTVs fully
under LCA apertures. Applying a threshold of TC25¼ 75%, i.e. our inclusion cri-
teria for deep H&N HT, the maximum CTV depth is 50mm.
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